1988
Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses.
Hafler DA, Ritz J, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. The Journal Of Immunology 1988, 141: 131-8. PMID: 2454256, DOI: 10.4049/jimmunol.141.1.131.Peer-Reviewed Original ResearchConceptsHuman anti-mouse antibodiesAnti-mouse responseAnti-mouse antibodiesHuman anti-mouse responseMultiple sclerosisChronic progressive multiple sclerosisPhase I clinical studyAnti-CD2 monoclonal antibodiesProgressive multiple sclerosisMore chronic diseasesT cell subpopulationsHuman immune responseT cell activationAcute immunosuppressionMAb infusionsT cell surfaceAnti-CD4Daily infusionsImmunologic responseImmunosuppressive effectsChronic diseasesIgG isotypeClinical studiesImmune responseLike antibodies
1987
Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Nuova Rivista Di Neurologia 1987, 57: 88-91. PMID: 3039645.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisMonoclonal antibody therapyMultiple sclerosisAntibody therapyChronic progressive multiple sclerosisHigh-dose intravenous cyclophosphamideMultiple sclerosis patientsForm of treatmentLong-term controlIntravenous cyclophosphamideSclerosis patientsClinical resultsSerious toxicityImmune parametersPilot trialCyclophosphamideNervous systemSclerosisTerm controlsPatientsMonoclonal antibodiesACTHOnly small numbersTherapyAdverse effects